Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Myriad Genetics, Inc.
< Previous
1
2
3
Next >
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 21, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
December 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 09, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
November 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
November 01, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
October 31, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
October 26, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QGEN
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
September 28, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
September 19, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
ILMN
MYGN
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
September 19, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 18, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
September 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.